Peyre 2012a.

Methods	A non‐randomised longitudinal study of methylphenidate use for up to 3 months
Participants	Number of participants screened: not stated Number of participants included: 173 Number of participants followed up: 136 Number of withdrawals: 37 Diagnosis of ADHD: DSM‐IV (subtype: combined (69.12%), hyperactive‐impulsive (8.09%), inattentive (22.79%)) Age: mean 10.74 (SD 2.74) IQ: > 70 Sex: 90% males, 10% females Methylphenidate‐naïve: not stated Ethnicity: not stated Country: France Comorbidity: conduct disorder (7.35%); ODD (50%); anxiety (32.35%); major depressive (22.06%); bipolar (1.47%); learning (33.09%) Comedication: none Sociodemographics: not stated Inclusion criteria Children and adolescents younger than 18 years who were eligible for MPH treatment for DSM‐IV ADHD and had parents able to speak and understand French. A subsample with complete data were re‐evaluated after optimal adjustment of MPH Exclusion criteria Mental retardation (IQ < 70) and chronic neurological disease
Interventions	Methylphenidate type: multiple‐dose immediate release or prolonged‐action once‐daily formulations (Ritaline LAR or ConcertaR Mean methylphenidate dosage: 0.82 mg/kg/day (SD 0.22) Administration schedule: not stated Duration of intervention: 15 days to 3 months Treatment compliance: not stated
Outcomes	Adverse effects were elicited through systematic questions (first about adverse events in general and then with a list of frequent adverse events) and medical chart review
Notes	Sample calculation: no Ethics approval: local ethics committee (Comite de Protection des Personnes Pitie‐Salpetriere) Funding: supported by grants from a Programme Hospitalier de Recherche Clinique (PHRC AOR 03006) and the Institut National de la Sante et de la Recherche Medicale (INSERM AAP‐RRC‐09). Vested interests: the author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of the article Key conclusions of the study authors: Child Behavior Checklist‐Dysregulation Profile (CBCL‐DP) was associated neither with poorer response to methylphenidate nor with more side effects. There were no differences in cognitive performance between participants with and without CBCL‐DP